Latest Update of Targeted Therapy in Lung Cancer

Latest updates in 1st-/2nd-line NSCLC therapy

The vast array of lung cancer targets and developed targeted therapies have produced volumes of clinical evidence on the first-line and second-line treatment of NSCLC. In this DIALOG webinar, Professor Jin-Hyoung Kang (Korea) shares some of the most promising and provocative clinical evidences in this area of research.

Estimated Time of Completion: 6 mins.

Clinical updates in exon 20 ins and other EGFR TKI-resistant NSCLC

EGFR mutations, including exon 20 and other heterogeneous groups of mutations, may confer resistance to EGFR TKI in NSCLC patients. In this DIALOG webinar, Professor Jin-Hyoung Kang (Korea) discusses the latest clinical evidence in the strategies to overcome these forms of mutations in NSCLC.

Estimated Time of Completion: 6-8 mins.

About the speaker

Professor Jin-Hyoung Kang is currently Professor and Chief of the Division of Medical Oncology at the Department of Internal Medicine and Seoul St Mary’s Hospital, the Catholic University of Korea, Seoul, South Korea. He is also the current President of the Korean Cancer Study Group and Team Leader of Lung Cancer Multidisciplinary Team in the Catholic Cancer Center.